 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Alternatives to meat, fish, and cheese have come a long way since I turned vegan,
  when falafel and spicy bean were the only burger options.
- ''
- I went vegan more than two years ago, when my burger choices were limited to falafel
  or bean-based.
- Tasmin Lockwood/Business Insider
- ''
- Fake meat derived from ...


I'm a vegan who spent a week cooking with fake meat and fish. Here's what I made with 7 plant-based alternatives and how I rated them.

---
- Science 37 teams up with Roches Foundation Medicine to boost home-based oncology
  trials
- badams
- Thu, 09/09/2021 - 04:48...


Science 37 teams up with Roche's Foundation Medicine to boost home-based oncology trials

---
- Esoteric Testing Market Size to Reach USD 66,214.79 Million by 2030 at a CAGR of
  12.5% - Valuates Reports Esoteric Testing Market Size to Reach USD 66,214.79 Million
  by 2030 at a CAGR of 12.5% - Valuates Reports PR Newswire BANGALORE, India, Aug.
  20, 2021 BANGALORE, India, Aug. 20, 2021...


Esoteric Testing Market Size to Reach USD 66,214.79 Million by 2030 at a CAGR of 12.5% - Valuates Reports

---
- While some in the life sciences industry create drugs and devices to tackle the
  Covid-19 pandemic, their colleagues are busy as ever raising money, testing new
  drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that
  may get overlooked amid the influx of Greater Boston life sciences and health care
  happenings.


The Petri Dish: Alkermes, Foundation Medicine see FDA approvals

---
- 'New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million
  in a Series B round led by Section 32, a California-based fund focused on biotech,
  technology, healthcare and life sciences. Total venture capital funding is now north
  of $70 million for the 6-year-old company. Double ...'


Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants

---
- Zicix (OTCMKTS:ZICX) and Natera (NASDAQ:NTRA) are both medical companies, but which
  is the better stock? We will compare the two companies based on the strength of
  their valuation, earnings, analyst recommendations, institutional ownership, dividends,
  profitability and risk. Profitability This table...


Head-To-Head Survey: Zicix (OTCMKTS:ZICX) and Natera (NASDAQ:NTRA)

---
- PharmChem (OTCMKTS:PCHM) and Natera (NASDAQ:NTRA) are both medical companies, but
  which is the better stock? We will compare the two companies based on the strength
  of their dividends, institutional ownership, earnings, profitability, analyst recommendations,
  risk and valuation. Profitability This ...


Reviewing Natera (NASDAQ:NTRA) and PharmChem (OTCMKTS:PCHM)

---
- Prior to joining Foundation Medicine in 2019 as CEO, Cindy Perettie was senior vice
  president in global oncology product strategy for drug giant Roche's oncology unit,
  overseeing one of the world's largest cancer-drug portfolios. She joined Foundation
  at a time of enormous growth for the genomic testing company, which aims to advance
  cancer care through precision therapies.


Cindy Perettie: 'Amazing people, amazing leaders, amazing science'

---
- 'Cancer detection test rivals Guardant Health Inc. and Foundation Medicine Inc.
  are headed back to court over their liquid biopsy technology. Redwood City-based
  Guardant (NASDAQ: GH) filed a lawsuit Monday in U.S. District Court in Delaware
  that claims that Foundation, which is owned by Genentech Inc.'


Showdown over 'liquid biopsy' patents lands two cancer test players in court again

---
- Takeda Pharmaceuticals (TAK) collaborates with Foundation Medicine for the development
  of latter's tissue and blood based companion diagnostics for use with Takeda's late-stage
  lung cancer portfolio.If approved, the appropriate companion diagnostics would be
  used to identify patients who may be eligible for mobocertinib for the treatment
  of patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC)
  and TAK's brigatinib for treatment of ALK+ mNSCLC.Through this collaboration, FoundationOne
  CDx and Liquid CDx will be developed for use with Takeda's therapies.


Watchers	872
52-Wk Low	$0.00
52-Wk High	$0.00

Market Cap	$0.00
Volume (M)	2,500.00
52-Wk High	$0.00
52-Wk Low	$0.00

FMI Foundation Medicine Inc.

About

Feed

News

Fundamentals